|
| Press Releases |
|
 |
|
| Thursday, July 20, 2023 |
|
|
エーザイ、「レカネマブ」について、アルツハイマー病の病理に対する効果、および皮下投与に関する最新の解析結果をアルツハイマー病協会国際会議2023（AAIC2023）において発表 |
| エーザイ株式会社とバイオジェン・インクは、このたび、アルツハイマー病（AD）治療剤レカネマブ（一般名、米国ブランド名：「LEQEMBI」）について、臨床第III相Clarity AD試験におけるレカネマブ投与によるアミロイドベータ（Aβ）の減少とパスウェイにおける下流のバイオマーカー変化の解析結果、ならびに現在開発中の皮下投与製剤に関する最新知見をアルツハイマー病協会国際会議2023において、発表したことをお知らせします。 more info >> |
|
|
Eisai Presents Latest Analysis of Lecanemab's Effect on Biomarker Changes and Subcutaneous Dosing at The Alzheimer's Association International Conference (AAIC) 2023 |
| Eisai Co., Ltd. and Biogen Inc. announced today that the results of a detailed analysis of the Phase 3 Clarity AD study demonstrated that lecanemab-irmb (generic name, U.S. brand name: LEQEMBI) treatment showed reductions in amyloid-beta (Abeta) pathology and downstream biomarker changes. more info >> |
|
| Wednesday, July 12, 2023 |
|
|
Eisai to Present the Latest Alzheimer's Disease Pipeline and Research |
| Eisai Co. Ltd announced today that the company will present the latest findings on its Alzheimer's disease (AD) pipeline and research, including Eisai's anti-amyloid beta (Abeta) protofibril* antibody for the treatment of Alzheimer's disease (AD). more info >> |
|
| Friday, July 7, 2023 |
|
|
Eisai: FDA Grants Traditional Approval for LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) supporting the traditional approval of LEQEMBI more info >> |
|
|
エーザイとバイオジェン・インク、「LEQEMBI(R)」（レカネマブ）がアルツハイマー病治療薬として米国FDAよりフル承認を取得 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）とバイオジェン・インク（Nasdaq：BIIB、本社：米国マサチューセッツ州ケンブリッジ、CEO：Christopher A. Viehbacher、以下 バイオジェン）は、このたび、米国食品医薬品局（FDA）が「LEQEMBI(R)」注射100 mg/mL溶液（一般名：レカネマブ）について、フル承認に向けた生物製剤承認一部変更申請（supplemental Biologics License Application：sBLA）を承認したことをお知らせします。 more info >> |
|
| Friday, June 30, 2023 |
|
|
New NEURii Research Collaboration Between Eisai, Gates Ventures, Health Data Research UK, Lifearc and The University of Edinburgh to Develop Digital Solutions for Dementia is Announced |
| Eisai, Gates Ventures, Health Data Research UK (HDR UK), LifeArc and The University of Edinburgh announced today a new two-year collaborative research agreement. more info >> |
|
| Thursday, June 29, 2023 |
|
|
エーザイ、Gates Ventures、Health Data Research UK、LifeArc、およびエジンバラ大学は認知症の課題解決に寄与するデジタル・ソリューション開発をめざす共同研究「NEURii」を開始 |
| エーザイ株式会社（本社：東京都）、Gates Ventures（米国、シアトル）、Health Data Research UK（英国、ロンドン、以下、HDR UK）、LifeArc（英国、ロンドン）、およびエジンバラ大学（英国、エジンバラ）は、このたび、2年間の新規共同研究契約を締結したことをお知らせします。 more info >> |
|
| Thursday, June 22, 2023 |
|
|
Eisai's "Nouknow" Will Continue to be Utilized for Brain Health Assessment as Part of The FY2023 Dementia Examination Project by Tokyo Bunkyo City |
| Eisai Co., Ltd. announced today that brain health checks utilizing "NouKNOW" (pronounced "NOH-NOH"), Eisai's digital tool for self-assessment of cognitive function, will continue to be promoted as part of the FY2023 dementia examination project, conducted by Bunkyo City, Tokyo. more info >> |
|
|
エーザイ、東京都文京区の2023年度認知症検診事業において「のうKNOW(R)」による脳の健康度測定を継続実施 |
| エーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫）は、このたび、東京都文京区(以下、文京区)が実施する2023年度認知症検診事業（以下、本事業）において、当社の認知機能のデジタルチェックツール「のうKNOW(R)」による脳の健康度測定が継続実施されることをお知らせします。 more info >> |
|
| Monday, June 12, 2023 |
|
|
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI (lecanemab-irmb) for the Treatment of Alzheimer's Disease |
| Eisai Co., Ltd. and Biogen Inc. announced today that the U.S. Food and Drug Administration's (FDA) Peripheral and Central Nervous System Drugs Advisory Committee (PCNS) voted unanimously that the data from Eisai's Phase 3 Clarity AD clinical trial confirms the clinical benefit of LEQEMBI (lecanemab-irmb) 100 mg/mL injection for intravenous use for the treatment of Alzheimer's disease (AD). more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
PlayX Showcases AI-Powered Transparency and Fairness at SiGMA Asia 2025 in Manila
May 21, 2025 22:00: JST
|
|
|
PlayX Showcases AI-Powered Transparency and Fairness at SiGMA Asia 2025 in Manila
May 21, 2025 21:00 HKT/SGT
|
|
|
GMG Approves AU$900k for Early Works for 10 Tonne per Annum Second Generation Technology Graphene Production Plant
May 21, 2025 20:29 HKT/SGT
|
|
|
Founders Metals Expands Upper Antino; Hits 33.0 m of 3.50 g/t Gold
May 21, 2025 19:39 HKT/SGT
|
|
|
米国株式投資の「新定番」ついに登場 インデックスファンドの次なる選択肢へ 米国株式アクティブ残高9年連続世界No.1ティー・ロウ・プライス[1]
May 21, 2025 16:00: JST
|
|
|
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
May 21, 2025 15:00 JST
|
|
|
GMG Launches G-Lubricant.com: A Transformative Graphene Energy Saving Solution for the Multi Trillion Dollar Global Liquid Fuel Industry
May 21, 2025 13:40 HKT/SGT
|
|
|
New RAV4 Makes World Premiere in Japan
May 21, 2025 14:09 JST
|
|
|
Naoris Protocol Begins Token Sale for First Post-Quantum Infrastructure Layer
May 21, 2025 13:00 HKT/SGT
|
|
|
SAP商業AI重塑企業營運
May 21, 2025 12:46 HKT/SGT
|
|
|
エーザイ、米国臨床腫瘍学会年次総会におけるがん領域の製品・開発品に関する発表
May 21, 2025 09:00: JST
|
|
|
Cambridge Isotope Laboratories Launches ISOLED-D: Revolutionary Deuterated Reagents for OLED Manufacturing
May 20, 2025 21:00 HKT/SGT
|
|
|
劍橋同位素實驗室推出ISOLED-D(TM)：革新的OLED製造用氘代試劑
May 20, 2025 21:00 HKT/SGT
|
|
|
剑桥同位素实验室推出ISOLED-D(TM)：革新的OLED制造用氘代试剂
May 20, 2025 21:00 HKT/SGT
|
|
|
IFCX Partners with Black Spade Capital to Drive Global Investment into Emerging Markets
May 20, 2025 19:19 HKT/SGT
|
|
|
|
|
More News >> |
|
|
|
|
|
